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1. Introduction 
Congenital diaphragmatic hernia (CDH) remains highly challenging. CDH is complex and 
often results in multi-system morbidity among survivors. In the past decade, significant 
technologic and medical advancements have enhanced the care of critically ill infants, 
including those born with CDH. Such advancements have led to improved survival rates 
among CDH infants at certain high-volume centres, but this has occurred at the expense of 
increased short- and long-term morbidities for patients who previously would have died.  
As collective knowledge has improved regarding the range of outcomes experienced by 
CDH survivors, the focus of much clinical research has shifted toward reducing survivor 
morbidity. Accordingly, many centres now offer multidisciplinary follow-up care for CDH 
survivors throughout infancy and early childhood in order to effectively diagnose and treat 
problems with the goal of maximizing the potential of the individual patient.  
The aim of this chapter is to describe the short- and long-term medical and 
neurodevelopmental outcomes of CDH survivors in infancy, childhood, and adolescence. 
We will also outline an approach to follow-up care for these highly complex and intriguing 
patients. 
2. Cardiopulmonary morbidity 
Because the diaphragmatic defect allows abdominal organs to herniate into the chest cavity 
during the time of bronchial and pulmonary artery branching, lung growth and 
development are subsequently impaired. Long-term pulmonary morbidity is variable and 
depends on the degree of underlying pulmonary hypoplasia as well as the severity of 
iatrogenic injury the lungs incurred in the neonatal period. Treatment with extracorporeal 
membrane oxygenation (ECMO) and patch repair of the diaphragm are also associated with 
persistent cardiorespiratory complications (Jaillard et al., 2003; Muratore et al., 2001). Up to 
50% of CDH survivors have long-lasting cardiopulmonary compromise, manifested as 
chronic lung disease, reactive airway disease, recurrent respiratory infections, and persistent 
pulmonary hypertension (Bagolan & Morini, 2007; Lally & Engle, 2008; Trachsel et al., 2005; 
Wischermann et al., 1995).  
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2.1 Chronic lung disease 
Lung structure is fundamentally altered in CDH due to the decreased number of bronchi 
and alveoli in the ipsilateral and, to a lesser degree, contralateral lung. Although the number 
of alveoli may increase over time (Beals et al., 1992), the number of larger airways does not, 
because bronchial development is complete at around 16 weeks of gestation (Reid, 1984). 
Postnatally, exposure to supplemental oxygen and mechanical ventilation results in 
pulmonary edema and protein leak, causing surfactant denaturation and lung injury. The 
suboptimal nutrition often experienced by critically ill infants may further worsen the 
problem. Taken together, these factors lead to the development of chronic lung disease - a 
highly significant problem for between 40% and 60% of CDH survivors (D’Agostino et al., 
1995; Kinsella et al., 1997; van den Hout et al., 2010).  
D’Agostino et al documented a 62% incidence of chronic lung disease among ECMO-treated 
CDH survivors at hospital discharge (D’Agostino et al., 1995). Bernbaum et al found a 
similar incidence of 63% with bronchopulmonary dysplasia (BPD, a form of chronic lung 
disease) at discharge, with only a slight improvement to 50% at age one. Strikingly, four of 
seven CDH-ECMO patients in this report continued to need artificial ventilatory support at 
one year of age (Bernbaum et al., 1995). In a study of infants with pulmonary hypertension, 
Kinsella et al found CDH infants to have a 41% incidence of chronic lung disease; this 
incidence was significantly higher than the incidence of chronic lung disease due to 
meconium aspiration syndrome or respiratory distress syndrome, and suggests the 
possibility of decreased total lung volume combined with more severe underlying 
parenchymal lung disease in the CDH group (Kinsella et al., 1997). Van den Hout et al 
documented a 41% prevalence of BPD in a study of 2078 CDH patients based on data from 
the CDH Study Group. The authors identified early gestational age, presence of cardiac 
abnormality, prenatal diagnosis, right-sided defect, low 5-minute Apgar score, and intial 
treatment with high-frequency ventilation as factors predictive of BPD in CDH survivors. 
They suggest that in addition to injury from volutrauma, barotrauma, and atelectotrauma, 
the hypoplastic lungs in CDH may be more susceptible to oxygen toxicity than lungs of 
newborns with other respiratory disorders (van den Hout et al., 2010). Differences in 
definitions of respiratory morbidity among survivors makes comparison of heterogenous 
studies somewhat difficult, yet overall morbidity ranges between 30-50% in general (Table 1).  
2.2 Reactive airway disease 
Approximately 25% of CDH infants demonstrate evidence of obstructive airway disease 
(Jaillard et al., 2003), with up to 45% of survivors showing asthma-like symptoms during 
childhood and adolesence (Davis et al., 2004; Trachsel et al., 2005). A study by Crankson and 
colleagues found 45% of 31 CDH survivors had recurrent wheezing attacks and required 
bronchodilators and/or inhaled steroids (Crankson et al., 2005). In another report, 
bronchodilators were prescribed in 40% and inhaled steroids in 35% of CDH survivors 
during the first year of life (Muratore et al., 2001). Lung function abnormalities appear to 
improve over time as compensatory lung growth occurs, although these data are limited to a 
relatively small number of patients (Peetsold et al., 2007; Trachsel et al., 2005). According to 
some experts, although CDH survivors may exhibit mild to moderate abnormalities on 
pulmonary function testing in late childhood through adulthood, they appear not to have an 
important reduction of total lung capacity, and may be expected to achieve normal exercise 
function (Ijsselstijn et al., 1997; Marven et al., 1998; Peetsold et al., 2007).  
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Author, Year, 
Study Design 
Definition 
ECMO-
treated 
Age at 
Follow-up 
Survival 
Respiratory 
Morbidity 
D’Agostino,  
et al. 1995 
 
Single-center, 
retrospective 
CLD: need for 
bronchodilators, 
diuretics, or 
supplemental 
oxygen for 
management of 
pulmonary 
symptoms 
yes (all) 
3, 6, and 12 
months 
80% at 
discharge 
(16 of 20) 
62% at 
discharge 
(n=16) 
 
30% at age  
1 year 
(n=13) 
Bernbaum,  
et al. 1995 
 
 
 
 
 
 
Single-center, 
retrospective 
BPD: (at 
discharge) greater 
than 30 days of 
supplemental 
oxygen and need 
for diuretics or 
bronchodilators 
for treatment of 
underlying CLD; 
(at follow-up) 
continued need 
for supplemental 
oxygen, diuretics, 
or 
bronchodilators 
yes (all) 
6 and 12 
months 
68% at 
discharge 
(19 of 28) 
63% at 
discharge 
(n=19) 
 
50% at age  
1 year 
(n=14) 
Kinsella, et al. 
1997 
 
 
Multicenter, 
randomized 
clinical trial 
CLD: oxygen 
requirement at 28 
days of age 
yes 
(number 
not 
reported) 
n/a 
53% at 
discharge 
(18 of 34) 
41% at day 28 
(n=34) 
van den Hout, 
et al. 2010 
 
 
Multicenter, 
retrospective 
BPD: oxygen 
requirement at 30 
days of age 
yes (29%) n/a 
76% at day 30 
(1586 of 2078) 
 
69% at 
discharge 
41% at day 30 
(n=1511) 
Table 1. Definitions and outcomes for studies documenting chronic lung disease (CLD) and 
bronchopulmonary dysplasia (BPD) in CDH survivors 
2.3 Oxygen dependency, respiratory infections, and tracheostomy 
A 2001 report by Muratore et al found 16% of CDH survivors required supplemental oxygen 
at the time of hospital discharge; more recent studies show this number to be closer to 40% 
to 50% (Colby 2004; Cortes et al., 2005). Coughing and frequent respiratory infections occur 
in 25% to 50% of children, particularly in the first year of life (Falconer et al., 1990; Kamata et 
al., 2005). A significant percentage of CDH patients are discharged home on diuretic therapy 
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for management of pulmonary edema (Muratore et al., 2001). Additionally, up to 4% of 
CDH infants ultimately require tracheostomy for respiratory failure in the setting of severe 
lung disease (Bagolan & Morini, 2007; Jaillard et al., 2003).  
2.4 Pulmonary hypertension  
Chronic pulmonary hypertension is one of the major complicating factors in CDH 
(Kinsella et al., 2005), and, according to one report, occurs in up to 21% of CDH infants 
(Kinsella et al., 2003). Recurrence of pulmonary hypertension beyond the neonatal period 
may lead to prolonged mechanical ventilation, a second ECMO run, or death (Dela Cruz 
et al., 1996; Lally & Breaux, 1995). In a small retrospective study of 8 infants with CDH, 
100% were found to have evidence of pulmonary hypertension on echocardiography 
(Benjamin et al., 2010). Overall mortality attributable to pulmonary hypertension 
approaches 50% in the CDH population (Kinsella et al., 1997; The Neonatal Inhaled Nitric 
Oxide Study Group (NINOS), 1997).  
In an attempt to correlate outcome with the severity of pulmonary hypertension among a 
cohort of CDH infants, Dillon et al investigated estimates of pulmonary artery pressures 
using serial echocardiography. Based on their findings, the authors propose that almost half 
of CDH patients will resolve their pulmonary hypertension within the first 21 days, and 
survival may be nearly 100% in this subpopulation. Conversely, a certain number of CDH 
infants will show persistent systemic or suprasystemic pressures despite all interventions 
(including ECMO), and survival among this group can be presumed zero. Finally, there 
exists a group with protracted pulmonary hypertension that is responsive to maximum 
medical management; survival rates for infants with this degree of pulmonary hypertension 
lie somewhere in between the two extremes (Dillon et al., 2004). 
Schwartz et al investigated the outcome of 21 CDH-ECMO survivors at a mean age of 3.2 years 
and found 38% with pulmonary hypertension based on echocardiographic findings. Of those, 
88% had some evidence of reactive airway disease and were on bronchodilators at the time of 
the study. There is, however, no mention of whether the patients were being treated with 
medication for pulmonary hypertension. The authors surmise that CDH infants may undergo 
a gradual increase in vascular smooth muscle proliferation leading to an increase in 
pulmonary arterial pressures over time. It remains unclear whether pulmonary vascular 
pressures eventually normalize as repair and growth progress (Schwartz et al., 1999).  
Management strategies for CDH infants who do not require mechanical ventilation but have 
pulmonary hypertension include inhaled nitric oxide (iNO) via nasal cannula and oral 
sildenafil, a highly selective phosphodiesterase inhibitor type 5 (Keller et al., 2004; Kinsella 
et al., 2003). Sildenafil has been used to treat older children and adults with pulmonary 
hypertension (Wilkens et al., 2001) by limiting degradation of cyclic GMP and thereby 
enhancing endogenous nitric oxide activity (Tulloh, 2009). Results from a 2007 study 
indicate sildenafil may augment cardiac output in infants with CDH during the first two 
weeks of administration (Noori et al., 2007).  
Though some reports document the presence of pulmonary hypertension in CDH beyond 
the neonatal period, little is known about the long-term structural pulmonary vascular 
abnormalities that remain, and how these structural abnormalities translate into clinical 
outcomes for older children and adults with chronic pulmonary hypertension following 
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CDH repair. More research is needed to assess the prevalence of persistent pulmonary 
hypertension, investigate the natural course of changing pulmonary pressures, determine 
the best methods for diagnosing pulmonary hypertension in CDH survivors, and determine 
the optimal dosing, timing, and indications for pharmacologic intervention.  
3. Growth and nutritional morbidity 
Numerous studies have documented the high incidence of gastrointestinal morbidity in CDH 
survivors (Fasching et al., 2000; Muratore et al., 2001; Van Meurs et al., 1993). Symptomatic 
gastroesophageal reflux (GER), feeding difficulties, and chronic growth failure necessitating 
supplemental enteral tube feedings are among the issues these infants and children face.  
3.1 Gastroesophageal reflux 
GER occurs in the vast majority of infants and children born with CDH, and is perhaps the 
most commonly encountered long-term problem among survivors. Several mechanisms 
have been proposed to explain the high incidence of GER in CDH, including fetal 
esophageal obstruction resulting in impaired esophageal motility, shortened esophageal 
length, disruption of the angle of His due to the abnormal location of the stomach in utero, 
and the complete or partial absence of the parahiatal diaphragm. The clinical presentation 
varies: some infants and children will experience recurrent vomiting, while in others GER 
may manifest as persistent bradycardic spells or aspiration pneumonia (Kieffer et al., 1995). 
Although many CDH survivors can be successfully managed with medical treatment, a 
significant number – up to 23% in one series – have severe GER requiring surgical 
intervention with fundoplication (Su et al., 2007). Factors associated with need for 
fundoplication are patch repair, ECMO treatment, and intrathoracic liver position (Diamond 
et al., 2007; Su et al., 2007).  
Recently, Maier et al attempted to determine whether performing preventive fundoplication 
at the time of CDH repair would impact GER symptoms in infancy. The authors found a 
clinically (but not statistically) significant difference between the degree of GER in the first 
postnatal year among those infants who did (n = 36) and did not (n = 43) have preventive 
fundoplication performed at the time of hernia repair, but there was no difference by the 
second year of follow-up. These authors concluded that preventive anti-reflux surgery 
cannot be recommended as standard of care (Maier et al., 2011).  
In contrast to the plethora of studies focusing on the gastrointestinal sequelae of CDH in 
infancy and childhood, there are relatively few studies describing outcomes among adult CDH 
survivors. Reports suggest a certain percentage of adult CDH survivors may have continued 
GER resulting in esophagitis and, in severe cases, Barrett’s esophagus. Vanamo et al found 
63% of adult survivors to have symptoms suggestive of GERD and 54% with evidence of 
esophagitis on endoscopy. Further, 2 of 11 patients with early postoperative GER developed 
esophageal stricture and underwent fundoplication (Vanamo et al., 1996). Steven et al 
described a case of esophageal adenocarcinoma in a 22 year-old CDH survivor; the 
malignancy was presumed to be related to long-standing GER associated with CDH (Steven et 
al., 2007). More studies are needed in adolescents and adults to determine whether the 
significant degree of GER experienced by CDH survivors in infancy and childhood remains a 
problem over time, and to what extent it impacts the health and wellbeing of adult survivors.  
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3.2 Feeding problems 
Protracted hospitalization combined with symptoms of GER and delayed initiation of oral 
feedings contributes to the development of feeding difficulties in CDH infants. In one series, 
oral aversion was observed in 25% of infants with CDH and contributed largely to growth 
failure (Jaillard et al., 2003). Van Meurs et al found 22% of CDH-EMO survivors to have 
”extreme food refusal” in the first two years of life, 75% of whom required long-term 
supplemental nutrition. In general, one-third to one-half of CDH infants require 
supplementation with enteral tube feedings to support growth in the first year of life, either 
via nasogastric or gastrostomy tube feedings (Muratore et al., 2001; Van Meurs et al., 1993).  
Symptoms of GER and resultant feeding problems may be more clinically apparent among 
CDH-ECMO survivors. In a study of 16 CDH-ECMO survivors, 81% were diagnosed with 
GER, and 69% were discharged requiring supplemental tube feedings (D’Agostino et al., 
1995). Similarly, in Van Meurs’ population of 18 CDH-ECMO survivors, at the time of 
hospital discharge, reflux precautions were in place for 22%, feedings were thickened with 
rice cereal for 22%, and 33% were being treated with metoclopramide (Van Meurs et al., 1993). 
3.3 Failure to thrive 
In conjunction with an increased metabolic demand due to pulmonary morbidity and 
underlying GER, feeding-related problems often result in failure to thrive. Muratore et al 
documented weight and height below the 25th percentile in more than 50% of CDH infants 
during the first year of life. In this study, ECMO treatment and need for oxygen at 
discharge were independent predictors of growth failure in the first postnatal year 
(Muratore et al., 2001). Others have similarly reported a relationship between ECMO and 
subsequent poor growth among CDH survivors; this finding is specific to the CDH-
ECMO population, as non-CDH ECMO children were shown to have essentially normal 
growth at 12 and 24 months in Van Meurs’ study (Nobuhara et al., 1996; Van Meurs et al., 
1993). Further, Van Meurs et al found that parental discontinuation of supplemental tube 
feedings contributed to findings of severe malnourishment at one year follow-up (Van 
Meurs et al., 1993). A significant proportion of CDH survivors remain below the 5th 
percentile for weight in the first three years (Kamata et al., 2005; Lund et al., 1994). Catch-
up growth can occur with aggressive management (Cortes et al., 2005), but poor growth 
remains a problem for a subset of patients. 
4. Musculoskeletal morbidity 
Chest wall and spinal deformities occur relatively commonly as a sequelae of CDH. One 
study of adult survivors found 48% with chest asymmetry, 27% with significant scoliosis, 
and 18% with pectus excavatum (Vanamo et al., 1996). The incidence increases with a larger 
diaphragmatic defect, presumably because repair of a large defect puts tension on the spine 
and interferes with normal development of the thorax. Other contributing factors include a 
smaller thoracic cavity on the affected side and increased work of breathing leading to 
development of a pectus abnormality via retraction of the cartilaginous anterior chest 
wall. For the most part, these deformities are mild and rarely require surgical 
intervention. However, the exact relationship between chest wall deformities and long-
term pulmonary function remains unclear. Trachsel et al found a correlation between 
moderate to severe chest wall abnormalities and impaired pulmonary functioning in 
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adulthood (Trachsel et al., 2005). Additionally, there is some evidence of abnormal lung 
function among patients with pectus excavatum (Koumbourlis & Stolar, 2004). 
5. Surgical morbidity 
The incidence of reherniation at the site of the diaphragmatic defect is directly related to the 
use of synthetic patch repair and ranges from 5% to 80% (Atkinson & Poon, 1992; Van 
Meurs et al., 1993). With the increasing popularity of minimally invasive surgical (MIS) 
techniques, studies have begun to investigate the short- and long-term outcomes following 
this approach. Using data from the CDH Study Group, Tsao et al looked at the in-hospital 
hernia recurrence rate following MIS and found a significantly higher proportion of 
recurrence in the MIS group compared with open repair; the authors estimated an almost 4-
fold increased odds of recurrence with MIS repairs. In this study, infants who required a 
patch repair had a higher recurrence rate, and MIS repairs that used a patch had the highest 
recurrence rate of approximately 9% (Tsao et al., 2011). The overall benefit for MIS in CDH 
patients remains to be determined. 
Timing of reherniation varies from months to years after the initial repair. Patients may 
present with gastrointestinal symptoms (feeding difficulties, vomiting), respiratory 
symptoms (coughing, wheezing), or they may be asymptomatic. Thus, regularly scheduled 
surveillance chest radiographs are advised (Lally & Engle, 2008; Moss et al., 2001).  
Almost invariably, infants with CDH have intestinal non-rotation or malrotation. 
Consequently, some are at risk for developing intestinal obstruction due to midgut volvulus 
if a Ladd’s procedure was not performed at the time of diaphragmatic repair. Postoperative 
intra-abdominal adhesions may also lead to intestinal obstruction – a life-threatening 
complication if not recognized and treated in a timely manner. 
6. Neurodevelopmental morbidity  
The underlying mechanisms of brain injury in CDH remain incompletely defined. Chronic 
lung disease, postnatal growth failure, and prolonged hospitalization are factors known to 
adversely affect neurodevelopment. In addition, most infants with CDH are exposed to 
perinatal and postnatal hypoxia, hypotension, hypercapnia, inflammation, and acidosis – all 
of which interfere with central nervous system development. Poor neurodevelopmental 
outcome in infants with CDH is likely the result of a combination of multiple interrelated 
factors. All CDH survivors should be considered at risk for cognitive delay and followed 
regularly in a multidisciplinary clinic. 
6.1 Neurodevelopmental outcomes among non-ECMO-treated CDH survivors  
In spite of heightened awareness about the potential for long-lasting adverse 
neurodevelopmental outcome in CDH survivors, most studies have focused on the 18- to 36-
month follow up period, with a considerable paucity of information detailing longer-term 
outcomes. Similarly, few studies describe the neurodevelopmental outcome of CDH survivors 
not treated with ECMO. Only recently have investigators begun to look at the developmental 
and psychological outcomes of survivors into late childhood and adolescence.  
One such series looking at CDH survivors between 8 and 12 years of age found only 54% to 
be functioning cognitively at expected school level. In addition, there was a higher 
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prevalence of emotional and behavioural problems among survivors in comparison to the 
general population (Bouman et al., 2000). In a study of adolescent CDH survivors, Jakobson 
and colleagues studied the visual and fine motor outcomes of CDH survivors between ages 
10 through 16 and found 13% had severe cognitive impairment, with the majority of the 
remaining showing poorer oral motor control and visual-motor integration skills as 
compared to peers (Jakobson et al., 2009). Notably, none of the survivors in these two 
studies were treated with ECMO as infants. 
6.2 Neurodevelopmental outcomes among CDH-ECMO survivors 
The relationship between CDH infants treated with ECMO and adverse neurocognitive 
outcome remains controversial. Some experts conclude that although ECMO can support 
the most critically ill infants, its use in the CDH population is associated with significant 
mortality and long-term morbidity (Bernbaum et al., 2005; Davis et al., 2004). On the 
contrary, others question whether adverse outcomes in this population may be due to the 
underlying disease process or an intrinsic neurologic abnormality rather than ECMO per se 
(D’Agostino et al., 1995; Jaillard et al., 2003; Lally & Engle, 2008).  
The physiologic basis for ECMO treatment leading to cognitive delay rests on several 
factors. First, infants who require ECMO to survive represent the sickest subset of patients 
in the newborn intensive care unit (NICU). They are at significant risk for hypoxia and 
hypoperfusion before and during ECMO treatment (Bagolan & Morini, 2007) and, 
therefore, are very likely subject to hypoxic-ischemic brain injury. Furthermore, ECMO 
support requires systemic anticoagulation (in all) and ligation of the carotid artery (in 
venoarterial). The increase in neurologic complications in infants treated with venoarterial 
ECMO (seizures, cerebral infarction) may be attributable to decreased cerebral blood flow 
resulting from ligation of the right internal carotid artery (Dimmitt et al., 2001). One 
report suggests that venovenous ECMO may be sufficient to support CDH patients, and 
when compared with venoarterial ECMO, is associated with decreased risk of neurologic 
impairment (Guner et al., 2009). 
A study by Van Meurs et al focusing on the outcome of 18 CDH-ECMO survivors between 
ages one and four years, 15 of whom underwent developmental testing, found 46% of the 
group to be normal, 20% with suspected developmental delays, and 13% with definitely 
abnormal developmental outcome (Van Meurs et al., 1993). In a report by Nobuhara and 
colleagues, 37% of 78 CDH survivors had developmental delay at follow-up; notably, 72% of 
the survivors with mild to moderate delays were treated with ECMO as neonates 
(Nobuhara et al., 1996). Similarly, McGahren et al described a statistically significant 
difference in neurologic abnormalities between CDH survivors who were and were not 
treated with ECMO: 67% of 12 CDH-ECMO infants had evidence of significant neurologic 
deficit at follow-up compared with 24% of 21 non-ECMO-treated CDH survivors 
(McGahren et al., 1997).  
A 2004 study of CDH-ECMO survivors found 19% to have severe neurodevelopmental 
problems, defined as speech, language, or motor delay, at a median age of 5 years. In this 
report, only 25% of 27 CDH children were free of significant neurodevelopmental deficit at 
follow-up (Davis et al., 2004). Similarly, among 149 5 year-old ECMO survivors, Nijhuis-van 
der Sanden et al found the 36 with CDH to have the worst outcomes: nearly 42% died, 72% 
had growth problems, and almost 16% had severe disabilities with only 37% functioning 
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normally (Nijhuis-van der Sanden et al., 2009). A recent study of 41 infants prospectively 
enrolled in an interdisciplinary follow-up program found 46% of CDH-ECMO survivors 
had deficits in developmental outcome at 24 months as well as an increased risk for 
psychomotor dysfunction and motor delays. Autism was diagnosed in 7% of this cohort 
(Danzer et al., 2010).  
Several studies document the relationship between ECMO and hypotonia in infancy and 
early childhood. A report by D’Agostino and colleagues followed 13 CDH-ECMO survivors 
into early childhood and found a significant number to have problems with hypotonia, 
which subsequently had a large impact on motor skill acquisition. Fifty-four percent had 
normal cognitive and motor outcomes at 12 months while 23% had delays in both areas 
(D’Agostino et al., 1995). In Nobuhara’s study, decreased lower extremity tone was the most 
common finding among CDH survivors with developmental delay (Nobuhara et al., 1996). 
Bernbaum et al studied a cohort of ECMO survivors and found the CDH-ECMO population 
to have significantly lower motor and slightly lower cognitive scores at one year of age 
compared with groups treated with ECMO for other reasons. In this study, 75% percent of 
CDH-ECMO infants with hypotonia at discharge continued to be hypotonic at age one, 
which affected the attainment of gross motor skills (Bernbaum et al., 1995).  
In a study by Tracy et al looking at the relationship between neuroimaging abnormalities 
and neurodevelopmental outcomes in a cohort of 45 CDH survivors, the authors found 
hypotonia to be the most frequently noted neurologic finding on physical examination. 
Hypotonia was present in 37% of survivors at age one and 71% of survivors at age three 
years. Motor problems seemed to be associated with hypotonia, as motor problems were 
diagnosed in 46% and 71% of the cohort at ages one and three, respectively. Additionally, 
motor problems at one year of age were correlated with abnormal findings on postnatal 
neuroimaging, continued respiratory compromise at age one, and a history of prolonged 
mechanical ventilation (Tracy et al., 2010). 
6.3 School-age follow-up of CDH survivors 
In a study looking at predictors of neurocognitive delay among a cohort of 16 school-age 
CDH survivors, 44% of the study population had evidence of persistent neurocognitive 
delay between ages 4 and 7 years. In this study, eight subjects underwent developmental 
testing at both 2 year and school age follow-up, and 50% had evidence of both early 
impairment and continued delay at school age. The remaining four subjects who scored 
within the average range on neurodevelopmental testing at 2 years remained with average 
scores at early school age. We found patch repair, ECMO treatment, days on ECMO, days of 
mechanical ventilation, and post-operative use of iNO to be associated with neurocognitive 
delay at early school age (Benjamin et al., 2010).  
6.4 Neuroimaging in CDH 
As brain imaging techniques have become more widely available, researchers have begun to 
study the effects of CDH on the developing central nervous system. A study looking at eight 
CDH survivors – none treated with ECMO – found all to have abnormalities on brain MRI, 
including ventricular dilatation, abnormal myelination of the posterior limb of the internal 
capsule, and abnormal signal in the white matter and basal ganglia (Hunt et al., 2004). Tracy 
et al showed that by age three years, 88% of CDH survivors who underwent brain MRI 
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studies had abnormal imaging findings, including extra axial fluid and periventricular 
leukomalacia. Additionally, abnormalities were present in 79% of those who underwent 
head computed tomography (CT) as a mode of neuroimaging (Tracy et al., 2010). Similarly, 
among a cohort of CDH-ECMO infants, 35% had central nervous system abnormalities on 
CT scan or at autopsy, including ventricular dilatation, intracranial hemorrhage, and 
cerebral atrophy. At two-year follow-up, the survivors were noted to have low-average 
scores on cognitive and motor testing (Ahmed et al., 1999). 
6.5 Sensorineural hearing loss 
Infants with CDH are known to be at high risk for sensorineural hearing loss (SNHL), 
though the precise etiology remains incompletely understood. In one of the earliest reports 
looking at infants with SNHL, Nield et al linked acidosis and severe hypoxia with the 
disease (Nield et al., 1986). In a study of infants with persistent pulmonary hypertension, 
alkalosis and prolonged duration of mechanical ventilation were found to be contributing 
factors (Hendricks-Munoz & Walton, 1988). In addition, high-frequency ventilation has been 
associated with SNHL (Lasky et al., 1998). 
The incidence of SNHL has been reported in up to 60% of CDH survivors in one report 
(Morini et al., 2008), and up to 100% in another (Robertson et al., 2002). It must be 
underscored that up to 50% infants labeled as having normal hearing may develop hearing 
loss later in infancy (Fligor et al., 2005; Robertson et al., 2002). This type of hearing loss is 
progressive, and therefore, for all infants with CDH, repeated hearing screening at 6-month 
intervals throughout infancy and early childhood is indicated to prevent significant speech 
and language delay.  
Among CDH infants, several reports link ECMO as a causative factor for the development 
of SNHL (Fligor et al., 2005; Nobuhara et al., 1996). A study by Rasheed et al found 100% of 
infants who were stabilized on ECMO pre-repair wore hearing aids compared with 22% 
who were treated with ECMO post-operatively. The authors suggest the difference may 
have been due to prolonged ECMO duration, more significant degrees of alkalosis and 
hyperventilation, and longer exposure to loop diuretics in the pre-repair group (Rasheed et 
al., 2001). Along with hypoxia and ECMO treatment, ototoxic medications commonly used 
in the NICU such as aminoglycoside antibiotics, loop diuretics, and neuromuscular blocking 
agents contribute to the high incidence of SHNL in this population (Masumoto et al., 2007). 
Overall, long-term neurodevelopmental morbidity among CDH survivors is highest among 
those who require patch repair and those treated with ECMO. Whether this is reflective of 
more severe primary disease or due to the greater number of associated complications in 
those two groups remains a subject of debate. In fact, multiple factors likely contribute to 
long-term morbidity, including perinatal, perioperative, and other postnatal events. The 
need for further studies to determine the role of ECMO in the CDH population is 
paramount in order to ensure the best outcomes for the majority of patients.  
7. Standardized treatment protocols for management of CDH 
Recently, studies have shown that standardized treatment protocols improve outcomes 
among critically ill patients by allowing more consistent care and reducing variability in 
decision-making practices (Delaney et al., 2008; Holcomb et al., 2001; Morris, 2003). 
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Although a universal approach to management of the CDH infant does not yet exist, several 
authors have documented their successes after adopting centre-specific CDH management 
protocols. In one such report, the authors demonstrate that the institution of a treatment 
protocol is independently associated with decreased mortality risk among infants with 
CDH; in their study survival rates increased significantly from 67% to 88% following 
implementation of the protocol (van den Hout et al., 2011). Tracy et al noted similar results 
after the development and execution of an evidence-based care protocol for CDH infants, 
with survival to discharge improving from 55% to 85% despite comparable expected 
survival rates between the pre-protocol and protocol groups (Tracy et al., 2010).  
With the aim of providing European neonatologists and pediatric intensive care physicians 
with a protocolized approach to the infant with CDH, the European task force for CDH 
(CDH EURO Consortium) recently drafted and published a consensus statement describing 
a standardized management protocol for CDH (Reiss et al., 2010). One may hope that a 
similar consensus statement will soon be realized in the United States and worldwide to 
allow more streamlined and evidence-based care for these highly complex patients.  
Given the small numbers of CDH cases occurring at individual centres, cooperation and 
collaboration between centres and internationally is essential to develop such protocols, and to 
enhance further research in this field via randomized controlled trials and investigation into 
long-term outcomes among survivors (van den Hout et al., 2011; Wright et al., 2011). 
8. Comprehensive follow-up for CDH survivors 
Prior to leaving the hospital, standard discharge practices should be applied to infants with 
CDH, including measurement of weight, length, and head circumference, physical and 
neurologic examinations, and newborn hearing screening. Pre-discharge chest radiography 
may be helpful for comparision over time and to monitor for asymptomatic reherniation at 
the repair site. An echocardiogram should be considered to evaluate for residual pulmonary 
hypertension and/or persistent elevations in right-sided heart pressures. Neuroimaging 
(brain MRI or head CT) may be considered for infants with abnormalities on ultrasound or 
neurologic examination, and for all ECMO survivors. For the CDH infant with symptomatic 
GER, imaging studies may be useful in delineating the severity of the problem to aid in 
deciding whether surgical intervention is warranted. All routine newborn immunizations, 
including pneumococal and influenza vaccines, should be administered according to 
recommeded guidelines. In addition, CDH survivors with chronic lung disease are 
suggested to receive palivizumab (Synagis) for prophylaxis against respiratory syncytial 
virus (American Academy of Pediatrics, 2009).  
Infants with CDH require long-term periodic follow-up evaluation to identify and 
effectively treat potential challenges; the goal is early and appropriate intervention to 
prevent additional disability and maximize developmental and cognitive outcomes. Ideally, 
this would be provided by a multidisciplinary team in a structured neonatal follow-up 
program in order to enhance communication and collaboration among providers while 
allowing the most comprehensive care possible. If such a program is not available, follow-
up appointments should be arranged with the infant’s primary care provider and with 
pediatric surgery at minimum. Follow-up with other specialists such as pediatric cardiology, 
pediatric neurology, and developmental-behavioral pediatrics should be arranged on an as-
needed basis depending on the infant’s degree of illness. 
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An article from the Section on Surgery and the Committee on Fetus and Newborn of the 
American Academy of Pediatrics advises that children with CDH be followed into adolescence 
to be sure that they are healthy and developing to the best of their potential. The Academy 
recommends specific medical tests as standard of care for CDH survivors, and the article 
includes a suggested schedule of follow-up, including annual neurodevelopmental screening 
and evaluation through school age (Table 2, Lally & Engle, 2008). 
 
Before 
Discharge 
1-3 mo 
After Birth 
4-6 mo 
After Birth 
9-12 mo 
After Birth 
15-18 mo 
After Birth 
Annual 
Through  
16 y 
Weight, length, 
occipital-frontal 
circumference 
X X X X X X 
Chest radiograph X If patched If patched If patched If patched If patched 
Pulmonary 
function testing 
  If indicated  If indicated If indicated 
Childhood 
immunizations 
As 
indicated 
throughout 
childhood 
X X X X X 
RSV prophylaxis 
RSV season 
during first 
2 years after 
birth (if 
evidence of 
chronic 
lung 
disease) 
X X X X X 
Echocardiogram 
and cardiology 
follow-up 
X 
If 
previously 
abnormal or 
on supple-
mental 
oxygen 
If 
previously 
abnormal or 
on supple-
mental 
oxygen 
If 
previously 
abnormal or 
on supple-
mental 
oxygen 
If 
previously 
abnormal or 
on supple-
mental 
oxygen 
If 
previously 
abnormal or 
on supple-
mental 
oxygen 
Head computed 
tomography or 
MRI 
If (1) 
abnormal 
finding on 
head 
ultrasound; 
(2) seizures 
/abnormal 
neurologic 
findings; or 
(3) ECMO 
or patch 
repair 
As 
indicated 
As 
indicated 
As 
indicated 
As 
indicated 
As 
indicated 
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Before 
Discharge 
1-3 mo 
After Birth 
4-6 mo 
After Birth 
9-12 mo 
After Birth 
15-18 mo 
After Birth 
Annual 
Through  
16 y 
Hearing 
evaluation 
Auditory 
brainstem 
evoked 
response or 
otoacoustic 
emissions 
screen 
X X X X 
Every 6 mo 
to age 3 y, 
then 
annually to 
age 5 y 
Developmental 
screening 
evaluation 
X X X X  
Annually to 
age 5 y 
Neurodevelop- 
mental 
evaluation 
X   X  
Annually to 
age 5 y 
Assessment for 
oral feeding 
problems 
X X 
If oral 
feeding 
problems 
If oral 
feeding 
problems 
If oral 
feeding 
problems 
If oral 
feeding 
problems 
Upper 
gastrointestinal 
study, pH probe, 
and/or gastric 
scintiscan 
Consider 
for all 
patients 
If 
symptoms 
If 
symptoms 
Consider 
for all 
patients 
If 
symptoms 
If 
symptoms 
Esophagoscopy  
If 
symptoms 
If 
symptoms 
If 
symptoms 
or if 
abnormal 
gastro-
intestinal 
evaluations 
If 
symptoms 
If 
symptoms 
Scoliosis and 
chest wall 
deformity 
screening 
(physical 
examination, 
chest radiograph, 
and/or computed 
tomography of 
the chest) 
   X  X 
Abbreviations: RSV, respiratory syncytial virus; CT, computed tomography; MRI, magnetic resonance 
imaging; ECMO, extracorporeal membrane oxygenation; GI, gastrointestinal. The neurosensory tests 
performed and frequency of surveillance may differ among infants because of variability in neurologic, 
developmental, and physiologic impairments. Follow-up should be tailored to each infant. 
Reproduced with permission from Pediatrics, Vol. 121, Pages 627-632, © 2008 by the American Academy 
of Pediatrics.  
Table 2. Recommended Schedule of Follow-up for Infants with CDH 
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Fig. 1. JCM, 9 day old term infant with CDH, on VA ECMO for 18 days, hospitalized for 
115 days. 
 
Fig. 2. JCM, CDH-ECMO survivor, age 2 ½, sharing a treat with his pal Lucy. 
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9. Conclusion  
CDH occurs because of a deceivingly simple anatomic defect; however, its effects often lead 
to severe consequences and lasting implications for affected infants and their families. 
Advancements in pediatric surgery and neonatal intensive care have led to improved 
overall survival in high-volume centres, but at the expense of increased long-term morbidity 
in survivors. Research is ongoing, particularly in search of an in utero cure for CDH, but also 
regarding the long-term outcomes of survivors as they progress through infancy and 
childhood to become adolescents and adults with CDH.  
CDH survivors provide a unique sense of satisfaction and joy to those who care for them; 
despite the difficulties, the potential for lasting health and well-being is great. These patients 
demand and deserve a multidisciplinary approach, both in the inpatient arena and follow-
up setting, with experts in neonatology, surgery, pulmonology, cardiology, and 
neurodevelopment working together to optimize outcomes and determine how to achieve 
the highest survival rates while allowing the best possible long-term outcomes for those 
who survive. 
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